logo
Share SHARE
FONT-SIZE Plus   Neg

Anacor Pharma Appoints Paul Berns As President And CEO - Quick Facts

Anacor Pharmaceuticals Inc. (ANAC: Quote) announced that its board has appointed Paul Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Berns succeeds David Perry who has served as Anacor's President and Chief Executive Officer since 2002.

Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies.

Anacor said that Berns has served as a member of the company's board since 2012. From March 2006 to August 2012, Berns served as President and Chief Executive Officer, and member of the Board of Directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012.

From June 2002 to July 2005, Berns was president, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and, from 1990 to 2000, Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Berns has been a director of Jazz Pharmaceuticals, PLC since 2010 and of XenoPort, Inc. since 2005.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber Technologies Inc., the rapidly growing ride-sharing service, has stumbled upon another problem in Japan. The Japaneses transport ministry has asked Uber to pull the plug on a pilot program in the city of Fukuoka. Last month, Uber started a pilot program in Fukuoka, Japan's sixth-largest city,... Firearms maker Smith & Wesson Holding Corp. (SWHC), Tuesday reported a drop in profit for the third quarter, as revenues and margins declined reflecting lower sales of long guns. However, earnings for the quarter came in ahead of Wall Street estimates as did revenues. Moving ahead, the company boosted... Target Corp (TGT) on Tuesday said it plans $2 billion of cost savings over the next two years, mainly at its corporate headquarters, as the discount retailer strives to boost profit and become a leaner outfit. Reports said that about $500 million of the savings would occur in the current year, and...
comments powered by Disqus
Follow RTT